Divalproex Sodium
Product Images NDC 0904-7181

6 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0904-7181). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 (Divalproex Sodium Extended Release Tablets Usp 1)

10 (Divalproex Sodium Extended Release Tablets Usp 1)
Chemical structure of divalproex sodium, showing the molecular arrangement with sodium ions and hydrocarbon chains.*
FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)
A cumulative distribution plot comparing percent reduction in CPS rate (vertical axis) against percent of patients (horizontal axis) for Divalproex Sodium versus placebo. The chart shows patient improvement or worsening, with Divalproex Sodium depicted by a solid line and placebo by a dashed line.*
FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)
A cumulative distribution plot depicting the percentage reduction in CPS (Complex Partial Seizure) rate versus the percentage of patients for Divalproex Sodium. The graph compares high dose and low dose effects, with high dose shown by a solid line and low dose by a dashed line. The vertical axis ranges from -100% to 100% reduction, indicating worsening or improvement, and the horizontal axis shows the percentage of patients from 0 to 100%.*
FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)
A bar graph comparing placebo and Divalproex Sodium Extended Release, showing numerical values on the y-axis with a statistically significant difference indicated (p=0.006). The placebo bar is lower than the Divalproex Sodium Extended Release bar, which is filled in black.*
FDA Label Image

250mg Carton Label (5284ecb4 6f0a 4388 8f78 A48e0c0123d6 01)

250mg Carton Label (5284ecb4 6f0a 4388 8f78 A48e0c0123d6 01)
Divalproex Sodium Extended-Release Tablets, USP label showing 250 mg strength with Valproic Acid Activity, unit dose packaging by Major Pharmaceuticals. The label indicates once-daily dosing, dispensed with a medication guide, containing 100 tablets. It includes storage instructions, dosage note to see product insert, and barcode. Distributed by Major Pharmaceuticals in Livonia, MI.*
FDA Label Image

500mg Carton Label (5284ecb4 6f0a 4388 8f78 A48e0c0123d6 00)

500mg Carton Label (5284ecb4 6f0a 4388 8f78 A48e0c0123d6 00)
Label for Divalproex Sodium Extended-release Tablets, USP 500 mg by Major Pharmaceuticals. The unit dose package contains 100 tablets (10 x 10) and is intended for once-daily dosing. The label includes NDC 0904-7182-61, valproic acid activity notation, usage instructions for pharmacists, storage conditions, warnings, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.